Using a mouse surrogate version of the antibody, it was found that TNFR2 agonism could generate strong anti-tumor responses by activating CD8+ T cells and NK cells with activity dependent on FcγR interactions, presumably mediated by cross-linking of the receptor. The gene discussed is CD8A; the disease is neoplasm.